Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Immune checkpoint inhibitors targeting the programmed cell death 1 receptor (PD-1) improve
survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). To identify …
survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). To identify …
[HTML][HTML] Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but
predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study, we …
predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study, we …
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Tumor mutational burden correlates with response to immune checkpoint blockade in
multiple solid tumors, although in microsatellite-stable tumors this association is of uncertain …
multiple solid tumors, although in microsatellite-stable tumors this association is of uncertain …
[HTML][HTML] Intron retention is a source of neoepitopes in cancer
AC Smart, CA Margolis, H Pimentel, MX He… - Nature …, 2018 - nature.com
We present an in silico approach to identifying neoepitopes derived from intron retention events
in tumor transcriptomes. Using mass spectrometry immunopeptidome analysis, we show …
in tumor transcriptomes. Using mass spectrometry immunopeptidome analysis, we show …
Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non–small-cell lung cancer
…, H Rizvi, F Dietlein, MX He, CA Margolis… - JCO precision …, 2019 - ascopubs.org
PURPOSE Heterogeneity in tumor mutational burden (TMB) quantification across sequencing
platforms limits the application and further study of this potential biomarker of response to …
platforms limits the application and further study of this potential biomarker of response to …
Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors
Prior data have variably implicated the inactivation of the mammalian SWItch/Sucrose Non-Fermentable
(mSWI/SNF) complex with increased tumor sensitivity to immune checkpoint …
(mSWI/SNF) complex with increased tumor sensitivity to immune checkpoint …
Integrative molecular characterization of resistance to neoadjuvant chemoradiation in rectal cancer
SC Kamran, JK Lennerz, CA Margolis, D Liu… - Clinical Cancer …, 2019 - AACR
Purpose: Molecular properties associated with complete response or acquired resistance to
concurrent chemotherapy and radiotherapy (CRT) are incompletely characterized. …
concurrent chemotherapy and radiotherapy (CRT) are incompletely characterized. …
Integrated molecular drivers coordinate biological and clinical states in melanoma
We performed harmonized molecular and clinical analysis on 1,048 melanomas and
discovered markedly different global genomic properties among subtypes (BRAF, (N)RAS, NF1, …
discovered markedly different global genomic properties among subtypes (BRAF, (N)RAS, NF1, …
Prenatal treatment of X-linked hypohidrotic ectodermal dysplasia using recombinant ectodysplasin in a canine model
CA Margolis, P Schneider, K Huttner, N Kirby… - … of Pharmacology and …, 2019 - ASPET
X-linked hypohidrotic ectodermal dysplasia (XLHED) is caused by defects in the EDA gene
that inactivate the function of ectodysplasin A1 (EDA1). This leads to abnormal development …
that inactivate the function of ectodysplasin A1 (EDA1). This leads to abnormal development …
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
… Margolis, 1, 2 Jake Conway, 2, 6 Meng Xiao He, 2, 6, 9 Haitham Elmarakeby, 1, 2 Felix
Dietlein, 1, 2 Diana Miao, 1, 2, 6 Adam Tracy, 2 Helen Gogas, 10 Simone M. Goldinger, 11 …
Dietlein, 1, 2 Diana Miao, 1, 2, 6 Adam Tracy, 2 Helen Gogas, 10 Simone M. Goldinger, 11 …